Foster & Motley Inc. Sells 12,772 Shares of Bristol Myers Squibb Company $BMY

Foster & Motley Inc. lowered its position in shares of Bristol Myers Squibb Company (NYSE:BMY) by 24.4% during the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 39,643 shares of the biopharmaceutical company’s stock after selling 12,772 shares during the period. Foster & Motley Inc.’s holdings in Bristol Myers Squibb were worth $2,138,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also bought and sold shares of the company. Darwin Wealth Management LLC bought a new stake in shares of Bristol Myers Squibb during the second quarter worth about $25,000. Harbor Capital Advisors Inc. raised its holdings in Bristol Myers Squibb by 107.2% in the 3rd quarter. Harbor Capital Advisors Inc. now owns 605 shares of the biopharmaceutical company’s stock valued at $27,000 after buying an additional 313 shares during the last quarter. Beacon Financial Strategies CORP acquired a new stake in Bristol Myers Squibb during the 4th quarter worth approximately $38,000. KERR FINANCIAL PLANNING Corp acquired a new stake in Bristol Myers Squibb during the 3rd quarter worth approximately $35,000. Finally, JPL Wealth Management LLC bought a new stake in Bristol Myers Squibb during the 3rd quarter worth approximately $36,000. Institutional investors and hedge funds own 76.41% of the company’s stock.

Key Bristol Myers Squibb News

Here are the key news stories impacting Bristol Myers Squibb this week:

• Positive Sentiment: Phase‑3 adolescent win for Camzyos strengthens BMY’s cardiovascular franchise — the SCOUT‑HCM trial met its primary endpoint with robust efficacy and no new safety signals, supporting label expansion into younger patients and longer commercial runway for the drug. Camzyos Adolescent Trial Success Might Change The Case For Investing In Bristol-Myers Squibb (BMY)
• Positive Sentiment: FDA approval for a Hodgkin’s lymphoma combination therapy provides an immediate commercial lift and validates oncology execution — another approved product can help offset patent cliffs elsewhere. Bristol-Myers Squibb Gets FDA Approval for Hodgkin’s Lymphoma Treatment
• Positive Sentiment: Value/income investor interest — Ariel Global Fund re‑added BMY citing pipeline strength and attractive valuation, which could signal renewed institutional demand. Ariel Global Fund Re-Added Bristol-Myers Squibb Company (BMY) on Pipeline Strength and Attractive Valuation
• Neutral Sentiment: Analyst/education pieces (Zacks, Yahoo) highlight potential upside from earnings surprises using Earnings ESP and note BMY’s recent outperformance relative to its history, but these are directional signals rather than new fundamentals. Bristol Myers Squibb (BMY) Ascends But Remains Behind Market: Some Facts to Note
• Neutral Sentiment: Market reports project growth in oncology and kidney cancer drug markets through 2030, underlining long‑term addressable market tailwinds for BMY but not immediate revenue changes. Kidney Cancer Drugs Market to Grow by $2 Billion During 2026-2030
• Negative Sentiment: Some outlets note mixed analyst sentiment and questions around near‑term execution; investors should weigh recent approval and trial wins against prior earnings misses and heavy leverage on the balance sheet. Bristol-Myers Squibb (BMY) faces mixed analyst sentiment despite strong momentum in healthcare industry

Analysts Set New Price Targets

Several equities analysts have recently issued reports on BMY shares. Barclays assumed coverage on shares of Bristol Myers Squibb in a research note on Thursday, February 19th. They set an “overweight” rating and a $75.00 price target for the company. Guggenheim restated a “buy” rating and issued a $72.00 price objective (up from $62.00) on shares of Bristol Myers Squibb in a report on Friday, February 6th. Citigroup raised their target price on Bristol Myers Squibb from $60.00 to $64.00 and gave the stock a “neutral” rating in a research report on Friday, February 6th. The Goldman Sachs Group reaffirmed a “neutral” rating and set a $57.00 target price (up from $51.00) on shares of Bristol Myers Squibb in a report on Tuesday, December 2nd. Finally, Wells Fargo & Company reiterated an “outperform” rating and issued a $60.00 price target (up from $55.00) on shares of Bristol Myers Squibb in a research report on Friday, February 6th. Nine investment analysts have rated the stock with a Buy rating, twelve have issued a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, the company has an average rating of “Hold” and a consensus target price of $61.41.

Bristol Myers Squibb Trading Up 1.4%

NYSE:BMY opened at $60.56 on Wednesday. Bristol Myers Squibb Company has a 52 week low of $42.52 and a 52 week high of $62.89. The company has a debt-to-equity ratio of 2.32, a quick ratio of 1.14 and a current ratio of 1.26. The firm’s fifty day moving average is $59.03 and its 200-day moving average is $52.45. The firm has a market cap of $123.65 billion, a P/E ratio of 17.55, a P/E/G ratio of 0.17 and a beta of 0.26.

Bristol Myers Squibb (NYSE:BMY) last announced its earnings results on Thursday, February 5th. The biopharmaceutical company reported $1.26 earnings per share for the quarter, missing analysts’ consensus estimates of $1.65 by ($0.39). The firm had revenue of $12.50 billion for the quarter, compared to the consensus estimate of $12.24 billion. Bristol Myers Squibb had a return on equity of 69.65% and a net margin of 14.64%.Bristol Myers Squibb’s quarterly revenue was up 1.3% on a year-over-year basis. During the same period in the prior year, the business earned $1.67 EPS. Bristol Myers Squibb has set its FY 2026 guidance at 6.050-6.350 EPS. Equities analysts expect that Bristol Myers Squibb Company will post 6.74 earnings per share for the current year.

Bristol Myers Squibb Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, May 1st. Stockholders of record on Thursday, April 2nd will be given a $0.63 dividend. The ex-dividend date of this dividend is Thursday, April 2nd. This represents a $2.52 annualized dividend and a dividend yield of 4.2%. Bristol Myers Squibb’s dividend payout ratio (DPR) is 73.04%.

Bristol Myers Squibb Company Profile

Bristol Myers Squibb is a global biopharmaceutical company headquartered in Princeton, New Jersey, focused on discovering, developing and delivering medicines for serious diseases. The company’s core activities include research and development, clinical development, manufacturing and commercialization of prescription pharmaceuticals across multiple therapeutic areas. BMS concentrates on advancing therapies in oncology, hematology, immunology, cardiovascular disease and specialty areas through both small molecules and biologics.

BMS’s marketed portfolio and late‑stage pipeline reflect a strong emphasis on cancer and immune‑mediated conditions.